These improvements were caused by the enhanced supply of precursors for GSH biosynthesis
For this purpose, the adjunctive therapeutic use of small molecules that either inhibit or stimulate eryptosis could represent a valid strategy for the treatment or prevention of pathological complications associated with erythrocyte dysfunction
In vivo studies in iron-deficient mice confirm this: erythrocytes exhibit increased PS exposure, reduced glutathione (GSH) levels, and accelerated clearance, with these defects reversed by iron repletion (Kempe et al., 2006)
Among the salient indications, inhaled NO is used for acute pulmonary vasoreactivity testing and severe hypoxia in pulmonary arterial hypertension (PAH), nitrates are used extensively in ischemic heart disease and heart failure, sGC stimulators and activators are used for PAH, and PDE5 inhibitors are used for erectile dysfunction, PAH and benign prostatic hyperplasia